GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » Forward PE Ratio

Hyloris Pharmaceuticals (XBRU:HYL) Forward PE Ratio : 0.00 (As of May. 20, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Forward PE Ratio?

Hyloris Pharmaceuticals's Forward PE Ratio for today is 0.00.

Hyloris Pharmaceuticals's PE Ratio without NRI for today is 0.00.

Hyloris Pharmaceuticals's PE Ratio for today is 0.00.


Hyloris Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Hyloris Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Forward PE Ratio Chart

Hyloris Pharmaceuticals Annual Data
Trend
Forward PE Ratio

Hyloris Pharmaceuticals Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Hyloris Pharmaceuticals's Forward PE Ratio

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyloris Pharmaceuticals's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Forward PE Ratio falls into.



Hyloris Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Hyloris Pharmaceuticals  (XBRU:HYL) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Hyloris Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (XBRU:HYL) Headlines